● neutral
Impact
PhasePhase 1b completed; Phase 2/3 TITAN study planned
Time to marketGemini is in Phase 1b/Phase 2 development. The Phase 2/3 TITAN study has not yet begun enrollment. If successful, potential FDA approval for AKI would likely be several years away, though the company reached an agreement with the FDA on an approval pathway in January 2026.
Gemini phosphorylated hexaacyl disaccharide (PHAD) Updated Nov 9
What to watch
Watch for the official start of the TITAN Phase 2/3 AKI study, which the company said in August 2026 was on track to begin later in the year. The company's cash runway extends into Q2 2027 per the Q3 2026 filing, so a financing event (dilutive offering) may be needed before the TITAN study produces data. Analyst consensus is bullish (6 Buy/Strong Buy, 1 Hold) with a mean price target of $124.25, but coverage is stale (no analyst action in 90+ days) and the stock trades near $3.89 after a 1-for-7 reverse split.
Bull case
- Phase 1 and Phase 1b studies met safety endpoints and showed statistically significant biomarker activity, including dose-dependent increases in IL-10 and normalization of cellular inflammation in CKD patients
- FDA agreement on an approval pathway for AKI reached in January 2026, providing regulatory clarity
- Independent market assessment estimated a $94 billion total addressable market for Gemini in Stage 2 and Stage 3 AKI
Bear case
- The Phase 2/3 TITAN study has not yet begun enrollment; the company faces significant clinical and regulatory execution risk
- REVB is a nano-cap with a market cap of approximately $2.5M, no revenue, and a going-concern risk flagged by analysts
- Cash runway extends only into Q2 2027, and the company has a history of dilutive financings and reverse stock splits (three in the past year)